tbuckley/cabot-search huggingface dataset:
A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.
Authors: Shinya Kimura, Haruna Naito, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa
Journal: Blood (2005)
Sequential SNP6.0 Microarray Analysis In Rai Stage 0 CLL Patients with Either Stable or Progressive Identifies Genomic Evolution In Both Cohorts
Authors: Matthew JJ Rose-Zerilli, Miqdad Rajibali, Helen Parker, Anton Parker, Anne Catherine Gardiner, Zadie Davis, Sarah Mold, Sharron Glide, Tracy Chaplin, Bryan D Young, David Graham Oscier, Jonathan C. Strefford
Journal: Blood (2010)
Hormonal gain control of a medial preoptic area social reward circuit
Authors: Jenna A McHenry, James M Otis, Mark A Rossi, J Elliott Robinson, Oksana Kosyk, Noah W Miller, Zoe A McElligott, Evgeny A Budygin, David R Rubinow, Garret D Stuber
Journal: Nature Neuroscience (2017)
IGF1R and phosphorylated IGF1R in HER2-positive breast cancer.
Authors: B. Browne, J. Crown, A. J. Eustace, S. Kennedy, N. O'Brien, A. Larkin, J. Ballot, T. Mahgoub, Z. Qadir, F. Sclafani, S. F. Madden, M. J. Kennedy, M. J. Duffy, N. O'Donovan
Journal: Journal of Clinical Oncology (2011)

587 Background: IGF receptor (IGF1R) signalling has been implicated in resistance to trastuzumab in HER2 positive breast cancer in vitro. However, two previous studies on HER2 positive breast tumors showed that IGF1R expression does not correlated with response to trastuzumab. The relationship between activation of the IGF1R and response to trastuzumab has not been examined in HER2 positive tumours. The aims of this study were to examine IGFIR and phosphorylated IGFIR (pIGF1R) in HER2 positive breast tumours, and to correlate IGFIR and pIGFIR with response to trastuzumab. Methods: Formalin-fixed paraffin-embedded tumour samples were obtained from 160 HER-2 positive breast cancer patients. Tissue microarrays were constructed using 4 cores from each specimen. Antigen retrieval was performed using pH6 antigen retrieval buffer (DAKO) and immunohistochemical (IHC) staining was performed on an autostainer (DAKO) using an IGF1R antibody and an antibody which detects phosphorylated IGF1R or insulin receptor (pIGF1R/IR). IHC results were correlated with tumor characteristics using Chi Square tests. Survival data was available for 94 HER2 positive early stage breast cancer patients who received trastuzumab, (median follow up 5.1 yrs). Survival analysis was performed using Kaplan Meier curves. Results: Membrane staining for IGF1R (mIGF1R) was detected in only 13.8 % of tumors (22/16), while varying degrees of cytoplasmic IGF1R (cIGF1R) staining were detected in all samples. mIGF1R was detected more frequently in larger tumors (>2 cm) (p=0.0414) and was detected in Grade 2 and 3 tumors but not in Grade 1 tumors (p=0.0239). pIGF1R/IR was detected in 48.8 % of tumors tested (78/160). pIGF1/IR was detected more frequently in node negative (57.6%) than node positive tumors (41.9%) although this difference did not achieve statistical significance (p=0.0592). In the trastuzumab treated cohort of HER2 positive early stage breast cancer patients (n=94), mIGF1R, cIGF1R and pIGF1R/IR did not correlate with patient survival (mIGF1R: p = 0.319; cIGF1R: p = 0.686; pIGF1R/IR: p = 0.504). Conclusions: Phosphorylated IGF1R/IR is detected in 49% of HER2 positive breast tumors but does not seem to predict response or resistance to trastuzumab in early stage breast cancer.
Selective transduction of astrocytic and neuronal CNS subpopulations by lentiviral vectors pseudotyped with Chikungunya virus envelope
Authors: Ioanna Eleftheriadou, Michael Dieringer, Xuan Ying Poh, Julia Sanchez-Garrido, Yunan Gao, Argyro Sgourou, Laura E. Simmons, Nicholas D. Mazarakis
Journal: Biomaterials (2017)
Tobacco-Product Use by Adults and Youths in the United States in 2013 and 2014
Authors: Karin A. Kasza, Bridget K. Ambrose, Kevin P. Conway, Nicolette Borek, Kristie Taylor, Maciej L. Goniewicz, K. Michael Cummings, Eva Sharma, Jennifer L. Pearson, Victoria R. Green, Annette R. Kaufman, Maansi Bansal-Travers, Mark J. Travers, Jonathan Kwan, Cindy Tworek, Yu-Ching Cheng, Ling Yang, Nikolas Pharris-Ciurej, Dana M. van Bemmel, Cathy L. Backinger, Wilson M. Compton, Andrew J. Hyland
Journal: New England Journal of Medicine (2017)

Noncigarette tobacco products are evolving rapidly, with increasing popularity in the United States.We present prevalence estimates for 12 types of tobacco products, using data from 45,971 adult and youth participants (≥12 years of age) from Wave 1 (September 2013 through December 2014) of the Population Assessment of Tobacco and Health (PATH) Study, a large, nationally representative, longitudinal study of tobacco use and health in the United States. Participants were asked about their use of cigarettes, e-cigarettes, traditional cigars, cigarillos, filtered cigars, pipe tobacco, hookah, snus pouches, other smokeless tobacco, dissolvable tobacco, bidis, and kreteks. Estimates of the prevalence of use for each product were determined according to use category (e.g., current use or use in the previous 30 days) and demographic subgroup, and the prevalence of multiple-product use was explored.More than a quarter (27.6%) of adults were current users of at least one type of tobacco product in 2013 and 2014, although the prevalence varied depending on use category. A total of 8.9% of youths had used a tobacco product in the previous 30 days; 1.6% of youths were daily users. Approximately 40% of tobacco users, adults and youths alike, used multiple tobacco products; cigarettes plus e-cigarettes was the most common combination. Young adults (18 to 24 years of age), male adults and youths, members of racial minorities, and members of sexual minorities generally had higher use of tobacco than their counterparts.During this study, 28% of U.S. adults were current users of tobacco, and 9% of youths had used tobacco in the previous 30 days. Use of multiple products was common among tobacco users. These findings will serve as baseline data to examine between-person differences and within-person changes over time in the use of tobacco products. (Funded by the National Institute on Drug Abuse and the Food and Drug Administration.).
HIF-1 Prevents Hematopoietic Cells from Cell Damage by Overproduction of Mitochondrial ROS after Cytokine Stimulation through Induction of PDK-1
Authors: Keita Kirito, Kozue Yoshida, Yongzhen Hu, Qiao Qiao, Kumi Sakoe, Norio Komatsu
Journal: Blood (2008)
Risk of Cerebrovascular Events in 178 962 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age
Authors: Chloe J. Bright, Mike M. Hawkins, Joyeeta Guha, Katherine E. Henson, David L. Winter, Julie S. Kelly, Richard G. Feltbower, Marlous Hall, David J. Cutter, Angela B. Edgar, Clare Frobisher, Raoul C. Reulen
Journal: Circulation (2017)

Background: Survivors of teenage and young adult cancer are at risk of cerebrovascular events, but the magnitude of and extent to which this risk varies by cancer type, decade of diagnosis, age at diagnosis, and attained age remains uncertain. This is the largest-ever cohort study to evaluate the risks of hospitalization for a cerebrovascular event among long-term survivors of teenage and young adult cancer. Methods: The population-based TYACSS (Teenage and Young Adult Cancer Survivor Study) (N=178,962) was linked to Hospital Episode Statistics data for England to investigate the risks of hospitalization for a cerebrovascular event among 5-year survivors of cancer diagnosed when 15 to 39 years of age. Observed numbers of first hospitalizations for cerebrovascular events were compared with that expected from the general population using standardized hospitalization ratios (SHRs) and absolute excess risks per 10 000 person-years. Cumulative incidence was calculated with death considered a competing risk. Results: Overall, 2782 cancer survivors were hospitalized for a cerebrovascular event—40% higher than expected (SHR=1.4, 95% confidence interval, 1.3–1.4). Survivors of central nervous system (CNS) tumors (SHR=4.6, 95% confidence interval, 4.3–5.0), head and neck tumors (SHR=2.6, 95% confidence interval, 2.2–3.1), and leukemia (SHR=2.5, 95% confidence interval, 1.9–3.1) were at greatest risk. Males had significantly higher absolute excess risks than females (absolute excess risks =7 versus 3), especially among head and neck tumor survivors (absolute excess risks =30 versus 11). By 60 years of age, 9%, 6%, and 5% of CNS tumor, head and neck tumor, and leukemia survivors, respectively, had been hospitalized for a cerebrovascular event. Beyond 60 years of age, every year, 0.4% of CNS tumor survivors were hospitalized for a cerebral infarction (versus 0.1% expected), whereas at any age, every year, 0.2% of head and neck tumor survivors were hospitalized for a cerebral infarction (versus 0.06% expected). Conclusions: Survivors of a CNS tumor, head and neck tumor, and leukemia are particularly at risk of hospitalization for a cerebrovascular event. The excess risk of cerebral infarction among CNS tumor survivors increases with attained age. For head and neck tumor survivors, this excess risk remains high across all ages. These groups of survivors, particularly males, should be considered for surveillance of cerebrovascular risk factors and potential pharmacological interventions for cerebral infarction prevention.
High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis
Authors: Susan Branford, Paul PS Wang, Wendy Tara Parker, David Yeung, Justine E Marum, Doris Stangl, Zoe Donaldson, Alexandra Yeoman, Nathalie Nataren, Ieuan Walker, Leanne Purins, Bradley Chereda, Christopher N Hahn, Hamish S Scott, Andreas Schreiber, Timothy P. Hughes
Journal: Blood (2015)
Correlation between overexpression of YY1 and downregulation of DR5 in prostate tumor arrays: novel mechanism of escape from immune surveillance
Authors: Sara Huerta-Yepez, Angeles Hernandez-Cueto, Mario Vega, Berenice Sanchez-Arellano, David Garcia-Herrera, Daniel Hernandez-Cueto, Cesar Gonzalez-Bonilla, Stavroula Baritaki, Massimo Libra, Benjamin Bonavida
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

2400 

Several mechanisms have been reported on tumor escape from immune surveillance. One such mechanism is the development of anti-apoptotic mechanisms to resist therapeutic apoptotic stimuli induced by cytotoxic immune leukocytes. Cytotoxic effector cells mediate their cytotoxic activities via death ligands (eg TNF-α, FasL, TRAIL) following interaction with their cognate receptors on the tumor cells. TRAIL is a member of the TNF-α superfamily and has been shown to be selectively cytotoxic to sensitive tumor cells, but not to the majority of normal tissues. TRAIL or agonist antibodies against DR4 or DR5 are in clinical trials. However, most tumors are resistant to TRAIL and need to be sensitized to undergo apoptosis. Several studies indicated that sensitization correlated with upregulation of DR5 expression. We have recently found that DR5 transcriptional regulation is under the control of the transcription repressor Yin Yang 1 (YY1) and inhibition of YY1 upregulates DR5 expression and sensitizes the tumor cells to TRAIL-induced apoptosis. YY1 has been shown by us to be of prognostic significance in prostate cancer (Seligson, et al., 2005, Int. J Oncol. 27(1):131-41). Therefore, based on our in vitro findings with tumor cell lines, we hypothesized that overexpression of YY1 in prostate tumors may correlate inversely with DR5 expression and regulate sensitivity to TRAIL. In order to corroborate this hypothesis, we have performed experiments to evaluate the expression of both the transcription factor YY1 and DR5 in prostate cancer tissue arrays containing formalin fixed, paraffin embedded sections obtained from the General Hospital No 25 from IMSS (Mexico, City). These arrays consisted of 30 untreated prostate carcinoma patients. Immunohistochemistry was performed using specific antibodies against of YY1 and DR5 and control IgGs. The arrays were scored, the intensity was recorded and the data were analyzed statistically. In contrast to adjacent normal tissues, the findings revealed that YY1 was overexpressed and in contrast DR5 expression was very low in the majority of prostate carcinoma patient specimens. The expression of YY1 was primarily in the nucleus and DR5 expression was in the cytoplasm. There was a significant inverse correlation between YY1 and DR5 expression ( p = 0.0001) in the same patient specimen. These findings suggest that the inverse relationship between YY1 and DR5 expression may be indicative of tumor escape from immune surveillance and may be of prognostic/diagnostic significance. In addition, the findings suggest that inhibitors of YY1 or inducers of DR5 may be new targets in prostate cancer when used in combination with immunotherapeutics.
Cas-L Suppresses Progression of Leukemia Induced by p210Bcr/Abl.
Authors: Sachiko Seo, Tetsuya Nakamoto, Takahiro Suzuki, Masataka Takeshita, Motoshi Ichikawa, Shigeru Chiba, Seishi Ogawa, Hiroaki Honda, Hideaki Oda, Mineo Kurokawa
Journal: Blood (2006)
Molecular Epidemiological Study in Pediatric Acute Myeloid Leukemia.
Authors: Helene Lapillonne, S. Lejeune-Dumoulin, Paola Ballerini, A.S. Goetgheluck-Gadenne, Anne Auvrignon, Hughes Leroy, Christine Perot, Francoise Mazingue, Mircea Adam, J.L. Lai, Luc Douay, Guy Leverger, Judith Landman-Parker, Claude Preudhomme
Journal: Blood (2004)
Doing What We Shouldn't: Medical Futility and Moral Distress
Authors: Nancy S. Jecker
Journal: The American Journal of Bioethics (2017)

The indiscriminate use of cardiopulmonary resuscitation (CPR), untempered by evidence about outcomes, has been called “irrational exuberance” (Rosoff and Schneiderman 2017). There is much to be sai...
The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.
Authors: Jingpan Pan, Alfonso Quintas-Cardama, Hagop Kantarjian, Peter Lamb, Ayalew Tefferi, Jorge Cortes, Francis Giles, Srdan Verstovsek
Journal: Blood (2006)
Navigating the Liminal State Between Life and Death: Clinician Moral Distress and Uncertainty Regarding New Life-Sustaining Technologies
Authors: Elizabeth Dzeng
Journal: The American Journal of Bioethics (2017)

Barg and colleagues (2017) describe the lack of a culturally scripted role for existence in a liminal state following LVAD implantation and how that creates uncertainty for patients at this borderl...
Improved survival with radiation therapy in early pancreatic adenocarcinoma
Authors: A. Artinyan, M. Hellan, P. Mojica-Manosa, J. Ellenhorn, J. Kim
Journal: Journal of Clinical Oncology (2007)

15036 Background: Although chemoradiation is often used following pancreatic cancer resection, recent studies have questioned the role of radiation therapy in this setting. The objective of this study was to determine the effect of adjuvant radiation therapy following pancreatectomy in patients with node-negative (N 0 ) pancreatic cancer. Methods: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify patients with N 0 pancreatic adenocarcinoma who had undergone curative-intent resection between 1988–2003. Kaplan-Meier survival curves were constructed to compare overall survival between patients ± adjuvant radiation therapy. Multivariate Cox regression analysis was performed to determine the prognostic significance of radiation therapy when additional clinicopathologic factors were assessed. The analysis also examined the potential treatment selection bias of patients with survival &lt;3 months. Results: Query of the SEER database identified 2342 surgical patients with N 0 disease. The median survival for these patients was 18 months. 889 (60.1%) patients were treated with radiation. There was no difference in gender or grade between radiation and non-radiation groups; however, radiation patients were younger (63 vs. 67 years, p&lt;0.001) and had a greater proportion of T3 lesions (p=0.002). Radiation patients had significantly improved survival compared to non-radiation patients (20.0 vs. 15.0 months, p&lt;0.001). On multivariate analysis, radiation therapy (HR 0.72, p&lt;0.001), age, grade, T-stage, and tumor location were independent predictors of survival. When patients with survival &lt;3 months were excluded from analysis, no difference in survival between radiation and non- radiation was noted (20.0 vs. 19.0 months, p=0.096). However, on subset analysis, patients with T3 tumors demonstrated improved survival with the addition of radiation (24.0 vs 16.0 months, p=0.002) and on multivariate analysis radiation therapy was an independent predictor of improved overall survival (HR 0.87, p=0.027). Conclusions: Radiation treatment is associated with improved survival in operable N 0 pancreatic cancer and its use should be considered in patients with early stage N 0 disease. The greatest impact of radiation therapy use appears to occur with T3 tumors. No significant financial relationships to disclose.
KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome
Authors: Juliana Popa, Philipp Erben, Georgia Metzgeroth, Georg Bolz, Martin C Mueller, Christoph Walz, Hans Peter Horny, Philipp Ströbel, Alexander Marx, Nicholas C.P. Cross, Andreas Hochhaus, Wolf-Karsten Hofmann, Andreas Reiter
Journal: Blood (2010)
Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))
Authors: Philippe Rousselot, Jean-Michel Cayuela, Christian Recher, Thibaut Leguay, Célia Salanoubat, Francis Witz, Magda Alexis, Maud Janvier, Mathilde Hunault, Philippe Agape, Christian Berthou, Eric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumedaly Reman, Bruno Lioure, Nicola Gökbuget, Dieter Hoelzer, André Delannoy, Renato Bassan, Jose-Maria Ribera, Sebastian Giebel, Sandrine Hayette, Oliver Ottmann, Hervé Dombret
Journal: Blood (2008)
Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies
Authors: Junya Kanda, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, Zhiguo Li, Nelson J. Chao, David A. Rizzieri
Journal: Blood (2010)
Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review
Authors: Dian Winkelhorst, Michael F. Murphy, Andreas Greinacher, Nadine Shehata, Taman Bakchoul, Edwin Massey, Jillian Baker, Lani Lieberman, Susano Tanael, Heather Hume, Donald M. Arnold, Shoma Baidya, Gerald Bertrand, James Bussel, Mette Kjaer, Cécile Kaplan, Jens Kjeldsen-Kragh, Dick Oepkes, Greg Ryan
Journal: Blood (2017)
Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Authors: Stuart S. Winter, Meenakshi Devidas, Brent Wood, Michael J. Borowitz, Mignon L. Loh, Barbara Asselin, John Murphy, Elizabeth Raetz, Naomi Winick, Stephen Hunger, William Carroll, Kimberly Dunsmore
Journal: Blood (2010)
Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease
Authors: Rakesh Bam, Angela Pennisi, Xin Li, Sharmin Khan, Yuping Wang, Wen Ling, Bart Barlogie, John Shaughnessy, Shmuel Yaccoby
Journal: Blood (2010)
Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.
Authors: W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar
Journal: Blood (2005)
Autoclaving‐Derived Surface Coating with In Vitro and In Vivo Antimicrobial and Antibiofilm Efficacies
Authors: Yajuan Su, Zelun Zhi, Qiang Gao, Meihua Xie, Meng Yu, Bo Lei, Peng Li, Peter X. Ma
Journal: Advanced Healthcare Materials (2017)

Biomedical device‐associated infections which engender severe threat to public health require feasible solutions. In this study, block copolymers consisting of antimicrobial, antifouling, and surface‐tethering segments in one molecule are synthesized and grafted on polymeric substrates by a facile plasma/autoclave‐assisted method. Hetero‐bifunctional polyethylene glycol (PEG) with allyl and tosyl groups (APEG‐OTs) is first prepared. PEGs with different molecular weights (1200 and 2400 Da) are employed. Polyhexamethylene guanidine (PHMG) which has excellent broad‐spectrum antimicrobial activity and thermal/chemical stability, is conjugated with APEG‐OTs to generate the block copolymer (APEG‐PHMG). Allyl terminated PHMG (A‐PHMG) without PEG segments is also synthesized by reacting PHMG with allyl glycidyl ether. The synthesized copolymers are thermal initiated by autoclaving and grafted on plasma pretreated silicone surface, forming permanently bonded bottlebrush‐like coatings. Both A‐PHMG and APEG 1200/2400 ‐PHMG coatings exhibit potent antimicrobial activity against gram‐positive/negative bacteria and fungus, whereas APEG 1200/2400 ‐PHMG coatings show superior antifouling activity and long‐term reusability to A‐PHMG coating. APEG 2400 ‐PHMG coating demonstrates the most effective in vitro antibiofilm and protein/platelet‐resistant properties, as well as excellent hemo/biocompatibility. Furthermore, APEG 2400 ‐PHMG greatly reduces the bacteria number with 5‐log reduction in a rodent subcutaneous infection model. This rationally designed dual‐functional antimicrobial and antifouling coating has great potential in combating biomedical devices/implant‐associated infections.
An In-Frame Deletion of Six Amino Acids and a Point Mutation in the Disintegrin Domain of ADAMTS-13 Associates with a Case of Congenital Thrombotic Thromocytopenic Purpura.
Authors: Zhenyin Tao, Leticia Nolasco, Bernardo Aubrey, Lawrence Rice, Joel F. Moake, Jing-Fei Dong
Journal: Blood (2004)
TRAILR Triggering by Human Antibodies Induces Apoptosis through an Early Cleavage of Mcl-1 and Caspase 3 in Myeloma Cells.
Authors: Catherine Pellat-Deceunynck, Patricia Gomez-Bougie, Sylvanne Daniels, Alexandrine Geffroy-Luseau, Regis Bataille, Martine Amiot
Journal: Blood (2005)
Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy.
Authors: John J. Powers, Jason A Dubovsky, Ling Zhang, Lynn C. Moscinski, P.K. Epling-Burnette, Eduardo M. Sotomayor, Javier Pinilla
Journal: Blood (2009)